McDonald's Corporation released internal data showing that 84 percent of households containing at least one GLP-1 medication user continue to visit its restaurants—a direct refutation of the bear thesis that haunted the stock.
GLP-1 agonists like Ozempic and Wegovy suppress appetite and have gained rapid adoption for weight management. Wall Street worried these drugs would crater fast-food traffic and margins. McDonald's data suggests otherwise.
The 84 percent figure is significant because it isolates the addressable risk: households with GLP-1 users are not abandoning the chain. This could reflect several dynamics—non-medicated household members still visiting, or GLP-1 users themselves buying coffee, sides, or occasional meals. Either way, the household economics hold.
McDonald's shares closed at $283.45 on Oct. 11. The stock has been held back by macro concerns about discretionary spending and the specific GLP-1 overhang. This data point provides institutional investors with a concrete counterargument to the demand-destruction narrative that has capped valuation multiples.
For equity holders, the implication is material. If the GLP-1 risk is overstated, and McDonald's holds its customer base even as drug adoption accelerates, the multiple compression driven by this fear may not persist. Watch same-store sales trends in coming quarters—if they hold flat or improve despite GLP-1 headwinds, the stock has room to re-rate higher.
